WO2011118994A3 - 간암 진단 마커 및 치료제로서의 엔엘케이 - Google Patents

간암 진단 마커 및 치료제로서의 엔엘케이 Download PDF

Info

Publication number
WO2011118994A3
WO2011118994A3 PCT/KR2011/002031 KR2011002031W WO2011118994A3 WO 2011118994 A3 WO2011118994 A3 WO 2011118994A3 KR 2011002031 W KR2011002031 W KR 2011002031W WO 2011118994 A3 WO2011118994 A3 WO 2011118994A3
Authority
WO
WIPO (PCT)
Prior art keywords
liver cancer
marker
diagnosis
nlk
expression
Prior art date
Application number
PCT/KR2011/002031
Other languages
English (en)
French (fr)
Other versions
WO2011118994A2 (ko
WO2011118994A9 (ko
Inventor
남석우
Original Assignee
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020110026618A external-priority patent/KR101315570B1/ko
Application filed by 가톨릭대학교 산학협력단 filed Critical 가톨릭대학교 산학협력단
Priority to US13/637,008 priority Critical patent/US8609626B2/en
Publication of WO2011118994A2 publication Critical patent/WO2011118994A2/ko
Publication of WO2011118994A9 publication Critical patent/WO2011118994A9/ko
Publication of WO2011118994A3 publication Critical patent/WO2011118994A3/ko

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11024—Mitogen-activated protein kinase (2.7.11.24), i.e. MAPK or MAPK2 or c-Jun N-terminal kinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

본 발명은 신규한 간암 진단용 마커 및 이의 용도에 관한 것이다. 보다 구체적으로, 본 발명은 간암세포에서 NLK(nemo like kinase)이 과발현됨을 확인함으로써 상기 NLK를 이용한 간암 진단용 마커, 이를 이용한 간암 진단용 조성물, 키트, 마이크로어레이 및 간임 진단 방법에 관한 것이고, 또한 상기 마커 유전자 또는 단백질의 발현을 감소시켜 간암을 예방 또는 치료할 수 있는 물질을 스크리닝하는 방법 및 상기 물질을 포함하는 간암의 예방 또는 치료용 조성물에 관한 것이다. 본 발명에 따른 간암 마커 유전자인 NLK는 정상 조직에 비해 간암 조직에서 특이적으로 발현양이 증가되어 있어, 상기 유전자의 발현을 억제할 경우, 간암세포에서 사이클린 D1 및 CDK2의 발현이 감소되고, G1/S 단계의 세포주기 진행이 억제됨과 동시에 세포의 증식 억제를 통해 간암의 예방 또는 치료할 수 있는 효과가 있으므로 상기 본 발명에서 발굴한 NLK 유전자는 간암의 진단 및 치료를 위한 타겟으로 유용하게 사용될 수 있다.
PCT/KR2011/002031 2010-03-25 2011-03-25 간암 진단 마커 및 치료제로서의 엔엘케이 WO2011118994A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/637,008 US8609626B2 (en) 2010-03-25 2011-03-25 NLK as a marker for diagnosis of liver cancer and as a therapeutic agent thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2010-0026751 2010-03-25
KR20100026751 2010-03-25
KR10-2011-0026618 2011-03-24
KR1020110026618A KR101315570B1 (ko) 2010-03-25 2011-03-24 간암 진단 마커 및 치료제로서의 ｎｌｋ

Publications (3)

Publication Number Publication Date
WO2011118994A2 WO2011118994A2 (ko) 2011-09-29
WO2011118994A9 WO2011118994A9 (ko) 2012-03-08
WO2011118994A3 true WO2011118994A3 (ko) 2012-04-26

Family

ID=44673953

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/002031 WO2011118994A2 (ko) 2010-03-25 2011-03-25 간암 진단 마커 및 치료제로서의 엔엘케이

Country Status (1)

Country Link
WO (1) WO2011118994A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104726593A (zh) * 2011-12-23 2015-06-24 上海吉凯基因化学技术有限公司 人nlk基因相关的用途及其相关药物
CN103173529B (zh) 2011-12-23 2015-04-29 上海吉凯基因化学技术有限公司 人nlk基因相关的用途及其相关药物
GB201212690D0 (en) * 2012-07-16 2012-08-29 Cancer Res Inst Royal Materials and methods for treating pten mutated or deficient cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EMAMI, K. H. ET AL.: "Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells", PROSTATE., vol. 69, no. 14, 1 October 2009 (2009-10-01), pages 1481 - 1492 *
JI, J. ET AL.: "Identification of microRNA-181 by genome-wide screening as a critical player in EpCAM-positive hepatic cancer stem cells", HEPATOLOGY., vol. 50, no. 2, August 2009 (2009-08-01), pages 472 - 480 *
JUNG, K. H. ET AL.: "Targeted disruption of Nemo-like kinase inhibits tumor Cell growth by simultaneous suppression of cyclin D and CDK2 in human hepatocellular carcinoma", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 110, no. 3, 1 June 2010 (2010-06-01), pages 687 - 696, XP002716964, DOI: doi:10.1002/JCB.22579 *
YASUDA, J. ET AL.: "Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS., vol. 308, no. 2, 22 August 2003 (2003-08-22), pages 227 - 233, XP004442965, DOI: doi:10.1016/S0006-291X(03)01343-3 *

Also Published As

Publication number Publication date
WO2011118994A2 (ko) 2011-09-29
WO2011118994A9 (ko) 2012-03-08

Similar Documents

Publication Publication Date Title
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007053648A3 (en) Compositions and methods for treating and diagnosing cancer
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
WO2012122370A3 (en) Compositions and methods useful for treating diseases
WO2010000364A8 (de) Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
MX2012004210A (es) Derivados de pirazol como moduladores del canal de calcio activado por liberacion de calcio.
MXPA05007651A (es) Composiciones y metodos para la inhibicion por arnsi de la molecula de adhesion intercelular-1.
BRPI0511139A (pt) compostos, composição farmacêutica que compreende os mesmos, método para inibir atividade de quinase aurora em uma célula e método para tratamento de um distúrbio mediado por quinase aurora em um paciente
WO2010048144A3 (en) Imaging and radiotherapy methods
WO2008142567A3 (en) Microrna molecules associated with inflammatory skin disorders
WO2020107002A3 (en) Methods for expansion of natural killer (nk) cell subset and related compositions and methods
WO2014100071A3 (en) Substituted pyrrolopyrimidines as hdm2 inhibitors
PH12013502369A1 (en) Diazacarbazoles and methods of use
WO2011133609A3 (en) Methods and kits to predict therapeutic outcome of btk inhibitors
WO2009114703A3 (en) Combination therapy for the treatment of cancer
EP4285911A3 (en) Methods and compositions for diagnosis and treatment of cancer
WO2009103067A3 (en) Compositions and methods to treat asthma
WO2012024396A3 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2012018643A3 (en) Compositions for proliferation of cells and related methods
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
WO2012067437A3 (ko) 간 절제를 위한 간 부피 증가용 조성물
MX2013010524A (es) Combinacion de oligonucleotido anti-clusterina con inhibidor hsp90 para el tratamiento de cancer de prostata.
WO2008092002A3 (en) Compositions and methods for treating and diagnosing pancreatic cancer
WO2011118994A3 (ko) 간암 진단 마커 및 치료제로서의 엔엘케이
WO2011021177A3 (en) Compositions and methods for prognosis and treatment of prostate cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11759743

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13637008

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 11759743

Country of ref document: EP

Kind code of ref document: A2